Fecha de publicación: 08/05/2025 Fuente: FierceBiotech NKGen Biotech CEO Paul Song, M.D., is putting his money where his mouth is, investing $2.65 million of his own cash to help accelerate the cash-strapped biotech’s phase 2 Alzheimer’s disease cell therapy trial.